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Infection with high-risk types (type 16 or type 18) of human papillomaviruses (HPVs) increases a patient’s risk of cervical cancer.
Given the importance of the cervix and the severe side effects resulting from traditional cancer therapies, this study aimed to
achieve targeted inhibition of viral oncogenes in tumor cells using small interfering RNAs (siRNA). To accomplish this, we
developed nine siRNAs against either the E6 or E7 genes of HPV-16 or HPV-18 in several combinations, yielding siRNAs targeting
16E6, 16E7, 18E6 and 18E7. We measured the effectiveness of the siRNAs by examining E6 or E7 mRNA expression after
transfection of the siRNAs into HPV-positive CaSki (HPV-16) or HeLa (HPV-18) cell lines. We found that the HPV-siRNAs
significantly reduced cell growth and colony formation in both cell lines. Flow cytometry analysis revealed a significant increase in
apoptosis. The siRNAs had no effect on cell growth, colony formation or apoptosis in HPV-negative C33A cells, demonstrating a
lack of off-target effects. In addition, an in vivo xenograft study showed that intra-tumoral injection of the siRNAs reduced tumor
growth in BALB/c nude mice. In conclusion, we have developed highly specific and potent HPV-siRNAs that successfully suppress
tumor growth and induce apoptosis in HPV-positive cervical cancer cells. siRNA treatment has potential for further development as
an adjuvant therapy for cervical cancer.
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Introduction
Cervical cancer is the second most common type of
malignancy among women worldwide. It affects nearly
half a million women each year, claiming a quarter of a
million lives.
1,2 Epidemiological evidence has proven that
previous infection with high-risk types of human papillo-
maviruses (HPVs) is the most significant risk factor for
cervical cancer. HPV DNA can be detected in more than
95% of cervical cancer and intraepithelial neoplasia
biopsies,
3 demonstrating the strong association of this
cancer with HPV infection.
HPVs are a group of more than 200 viruses.
4 They are
small, non-enveloped DNA viruses, 55nm in diameter.
3–6
They are called papillomaviruses because certain types
can cause warts or papillomas, which are benign
(non-cancerous) tumors. HPVs that cause common hand
and foot warts are different from those that cause growths
in the genital area. Some types of HPV, such as type
16 and 18, are associated with cancer development and
consequently have been termed high-risk or carcinogenic
HPVs.
3–6 High-risk HPVs have different characteristics to
those associated with benign lesions. First, the expression
of E6 and E7 viral oncogenes is tightly regulated by the
E2 protein during the normal life cycle of HPVs; however,
in high-risk HPVs, expression of the E2 gene is disrupted
during integration of the viral genome into the host cell,
leading to aberrant expression of E6 and E7. Further-
more, the E6 and E7 proteins of high-risk HPVs have a
much higher affinity to the tumor suppressor proteins p53
and Rb than those of other HPVs. The E6 protein binds
to p53 and targets it for accelerated ubiquitin-mediated
degradation.
3–6 The E7 protein binds to the hypopho-
sphorylated form of Rb, resulting in the disruption of
Rb/E2F complexes and reversal of the G1/S cell-cycle
checkpoint.
3–6 Consequently, these viral oncogenes are
potential targets for gene therapy of HPV-infected
cancers.
RNA interference was first described in animals in 1998
and has now been widely used in functional genomics
studies. RNA interference is the post-transcriptional
silencing of gene expression by double-stranded RNA
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7,8 Small interfering RNAs (siRNAs) are
potentially applicable for the targeting of genes involved
in any number of human diseases.
9 Although several
studies have reported the effects of HPV siRNAs
on cervical cancer,
10–15 those reports were only for
type-16
10,13,15 or type-18.
11,14 Furthermore, many of them
lack HPV-negative cells as controls
11,13 or short of
animal studies.
12,14,15 In this study, we designed nine
HPV-siRNAs against the E6 or E7 oncogenes of the
HPV-16 or HPV-18 virus. We investigated their specificity
and efficacy on HPV-infected and non-infected cervical
cancer cells. The siRNAs demonstrated highly potent and
specific inhibition of HPV-positive tumor growth in vitro
and in vivo, although they had no effect on HPV-negative
cells. We discuss the specific siRNA design for strong
suppression of the HPV E6 and E7 genes.
Materials and methods
Construction of siRNA plasmids
The pTOPO-U6 or pTOPO-U6II vector was used to
construct HPV-siRNA plasmids as previously described,
with few modifications.
16,17 Briefly, a 17B22 sense and
antisense hairpin oligonucleotide was generated comple-
mentary to specific mRNA of each gene. This hairpin
oligonucleotide was separated by an eight-nucleotide
spacer composed of a restriction enzyme cutting site
that facilitated cloning into the pTOPO vector. A total
of nine HPV-siRNA plasmids were constructed with
sequences targeting HPV16-E6 (three plasmids, 16E6-249,
 164 and  161), HPV16-E7 (three plasmids, 16E7-666,
 629 and  628), HPV18-E6 (one plasmid, 18E6-119) and
HPV18-E7 (two plasmids, 18E7-666 and  674) genes. An
18E6-Scramble plasmid that has the same nucleotide
composition as 18E6-119 but a randomized sequence
was designed as a control. The coding sequences for the
HPV-siRNAs were empirically determined and analyzed
by BLAST to ensure that they did not have sequence
homology with host genes. The siRNA sequences are
listed in Table 1.
Cell lines and plasmid transfection
Cervical cancer cell lines HeLa (HPV18-positive), CaSki
(HPV16-positive) and C33A (HPV-negative) were used in
this study. These cells were cultured in minimum essential
medium, Roswell Park Memorial Institute Medium-1640
and Dulbecco’s Modified Eagel Medium for HeLa, Caski
and C33A cells, respectively (Gibco BRL, Rockville,
MD). All media were supplemented with 10% FCS and
1% antibiotics and maintained at 371C in a humidified
incubator containing 5% CO2. To determine the transfec-
tion efficacy, the pGFP plasmid (BD Biosciences Clotech,
CA) was used. For plasmid transfection, cells were seeded
at a density of 1 10
6 in a 100-mm
2 dish and cultured for
16h. When cell confluence reached 60%, they were
transfected with 6mg of an HPV-siRNA plasmid or
control vector using Lipofectamine 2000 reagent (Invitro-
gen, Carlsbad, CA) in OPTI-MEM medium (Invitrogen)
for 6h. The medium was then replaced with fresh medium
and normal cell culture was resumed.
RNA extraction and reverse transcription (RT-PCR)
analysis
The mRNA expression of E6 and E7 was determined by
RT-PCR, similar to previous descriptions.
18 In brief, total
RNA was extracted with TRIzol reagent (Gibco BRL).
The complementary DNA was synthesized by incubation
of samples in 371C for 1h in a buffer containing 50mM
Tris, pH 8.4, 75mM KCl, 3mM MgCl2, 300ng of RNA,
0.2mg oligo-dT, 10mM DTT, 0.5mM dNTP, 10 units of
RNase inhibitor and 50 units of reverse transcriptase.
For each PCR run, a master mixture was prepared with
1x TaqMan buffer, 5mM MgCl2, 200mM dNTP, 300nM of
each primer, 1 unit of AmpliTaq Gold DNA Polymerase
and 3ml of complementary DNA solution in a total of
30ml. Primer sequences for each gene are listed in Table 2.
PCR reactions were carried out with specific primers and
the following settings: 30 cycles at 941C for 40s, 561C for
40s and 721C for 1min, using a Tpersonal thermocycler
(Biometra, Gottingen, Germany). The PCR products
were analyzed by 2% agarose gel electrophoresis, stained
with ethidium bromide, photographed at 254nm and the
Table 1 Sequence design of HPV-siRNAs
HPV-siRNA Nucleotides siRNA sequence
16E6-249 (249-267) 19 50-TTATGCATAGTATATAGAGgaagcttgCTCTATATACTATGCATAA-30
16E6-164 (164-183) 20 50-CTAGGCAAACAACTATACATGATAgaagcttgTATCATGTATAGTTGTTTGC-30
16E6-161 (161-178) 18 50-CTAGCTGCAAACAACTATACATgaagcttgATGTATAGTTGTTTGCAG-30
16E7-666 (666-682) 17 50-GAAATAGATGGTCCAGCgaagcttgGCTGGACCATCTATTTC-30
16E7-629 (629-645) 17 50-CTAGCTCTACTGTTATGAGCAgaagcttgTGCTCATAACAGTAGAG-30
16E7-628 (628-649) 22 50-CTAGTCTCTACTGTTATGAGCAATTAgaagcttgTAATTGCTCATAACAGTAGAGA-30
18E6-119 (119-125) 17 50-CCAACACGGCGACCCTAgaagcttgTAGGGTCGCCGTGTTGG-30
18E6-Scramble 17 50-CACCACATACCGCACGGgaagcttgCCGTGCGGTATGTGGTG-30
18E7-666 (666-682) 17 50-CTAGTTCTATGTCACGAGCAAgaagcttgTTGCTCGTGACATAGAA-30
18E7-674 (674-690) 17 50-CTAGCACGAGCAATTAAGCGAgaagcttgTCGCTTAATTGCTCGTG-30
Abbreviations: HPV, human papillomaviruse; siRNA, small interfering RNA.
The position of each siRNA target sequence from the transcriptional start site is shown in parentheses. All siRNAs sequences have
been confirmed by BLAST to have no homology to any part of the human genome. The nucleotide sequences in lowercase letters
indicate the spacer for the hairpin folding area.
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Cancer Gene Therapydensity of each band was measured. For quantification,
the density of each gene was calibrated to the control
vector after normalization to the internal actin level.
Cell growth and colony formation assay
To determine cell growth, cell number and viability were
determined daily by staining with 0.25% trypan blue and
counting with a hemocytometer. For the colony forma-
tion assay, a total of 1000 cells, transfected with either
a HPV-siRNA or control vector plasmid, were seeded
on six-well plates and allowed to grow for 10 days in
complete culture medium containing 30% fetal bovine
serum. The cell colonies were then stained with 5% crystal
violet (Sigma, St Louis, MO) for 15min, washed with
double distilled dH2O and counted. For quantification,
Sorenson’s solution (0.03mM tri-sodium citrate, 0.0195 N
HCl, 45% ethanol) was added to each well to remove the
dye from cells. After a 30-min incubation, the solution
was transferred to a well in a 96-well plate and its
absorbance was measured at 570nm by a spectrometer.
Flow cytometry
Cells treated with an HPV-siRNA or control vector
plasmid were harvested and washed with phosphate-
buffered saline (PBS). The pellets were fixed with ethyl
alcohol and PBS at  201C (EtOH/PBS¼3/1). The pellets
were then suspended and incubated with 0.5% Triton
X-100 and 0.05% RNase in PBS at 371C for 1h. The
pellets were then incubated with 40mgml
–1 propidium
iodide for 30min. Samples were analyzed by flow
cytometry (Becton Dickinson, San Jose, CA). The cell-
cycle distribution was determined using Cell Quest Pro
and ModiFit softwares.
Xenografts
BALB/c AnN-Foxn1nu/CrlNarl nude mice were used. A
4B6-week-old nude mouse was subcutaneously injected
with 5 10
6 HeLa cells at each side of the upper hind limb
region to generate solid tumors at both sites. Three days
after tumor cell injection, one tumor was injected with an
HPV-siRNA plasmid in 50ml PBS, following by boosters
of 25mg plasmid in 25ml PBS twice a week for a total of 30
days. The other tumor was injected with a control vector
plasmid following the same schedule as the experimental
group. The tumor dimensions were measured every 2B3
day with calipers and calculated as length   width  
height.
Statistical analysis
A two-ay ANOVA test was used to examine the
association of siRNA and control plasmids. All P-values
were two-sided, and the significance level was set at a
Po0.05.
Results
Inhibition of E6 and E7 expression by HPV-siRNAs
CaSki (HPV16-positive) or HeLa (HPV18-positive) cells
were used to examine the effects of E6 or E7 gene
knockdown by HPV-siRNAs. A total of nine HPV-
siRNAs were designed and their effects on E6 or E7 gene
expression were determined by RT-PCR analysis after
transfection of each specific siRNA into cells. Results are
shown in Figure 1. The siRNAs 16E6-164 and 16E6-161
showed effective knockdown of HPV16-E6 gene expres-
sion: 31 and 32% of control levels, respectively, at 24h.
Similarly, the siRNAs 16E7-629 and 16E7-628 showed
effective knockdown of HPV16-E7 gene expression:
31 and 22% of control levels, respectively, at 24h
(Figure 1b). The siRNA 18E6-119 showed effective
knockdown of HPV18-E6 gene expression: 37% of
control levels at 24h (Figure 1c). The siRNAs 18E7-666
and 18E7-674 showed effective knockdown of HPV18-E7
gene expression: 37 and 9% of control levels, respectively,
at 24h (Figure 1d). We, therefore, obtained at least
one effective siRNA for each viral oncogene in each type
of HPV.
Suppression of HPV-positive cell growth
by HPV-siRNAs
We examined the potential alteration of cellular pheno-
types after E6 or E7 knockdown by transfection of these
siRNA plasmids. The transfection efficacy was deter-
mined by the evaluation of green fluorescent protein
expression in pGFP-transfected cells. Results were shown
in the Figure 2. As shown, the fluorescent light presented
in any of the cell types (HeLa, CaSki or C33A) was
comparable, with approximately 70% of the total cells.
These results suggest that the plasmid delivery ability
among these three cell types was similar.
Figure 3 shows the effect on cell growth. As shown in
Figure 3a, consistent with the observed knockdown of
gene expression (Figure 1a), the two specific 16E6-
siRNAs (16E6-164, 16E6-161) caused significant inhibi-
tion of cell growth, with approximately 70% reduction at
day 2 and 85% at day 3 after transfection. Similarly, two
of the specific 16E7-siRNAs (17E7-629, 16E7-628) caused
substantial inhibition of cell growth, with approximately
75% reduction at day 2 and 90% at day 3 (Figure 3b).
The specific 18E6-siRNA, 18E6-119, also caused sub-
stantial inhibition of cell growth, with 74 and 490%
reduction at day 2 and day 3, respectively (Figure 3c).
Table 2 List of primer sequences used for the analysis of HPV E6 or
E7 gene expressions by RT-PCR
HPV gene Primer sequences
HPV16E6 F: 50-AATGTTTCAGGACCCTACGG-30
R: 50-TCAGGACACAGTGGCTTTTG-30
HPV16E7 F: 50-TTTGCAACCAGAGACAACTGA-30
R: 50-GCCCATTAACAGGTCTTCCA-30
HPV18E6 F: 50-GCGACCCTACAAGCTACCTG-30
R: 50-GTTGGAGTCGTTCCTGTCGT-30
HPV18E7 F: 50-GCATGGACCTAAGGCAACAT-30
R: 50-TGTTGCTTACTGCTGGGATG-30
Actin F: 50-GTGGGGCGCCCCAGGCACCA-30
R: 50-CTCCTTAATGTCACGCACGATTTC-30
Abbreviations: HPV, human papillomaviruse; RT-PCR, reverse
transcription PCR.
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caused substantial growth inhibition, with 480% reduc-
tion at day 2 and 490% at day 3 (Figure 3d). These
results are consistent with the level of knockdown caused
by each specific HPV-siRNA (Figure 1).
To examine whether these siRNAs specifically inhibit
growth in HPV-infected cells, we examined the growth
of HPV-negative cervical cancer cells (C33A) after
transfection with the siRNAs. All four siRNAs against
HPV-16 (16E6-164, 16E6-161, 16E7-629 and 16E7-628)
(Figure 3e) or the three siRNAs against HPV-18 (18E6-
119, 18E7-666 and 18E7-674) (Figure 3f) had minimal
effect (o10% inhibition) on cell growth. These results
suggest that these siRNAs have high specificity for HPV
genes and have almost no effect on cells not infected
with HPV.
Suppression of HPV-positive colony formation
by HPV-siRNAs
To validate the cell growth results, we tested the same
siRNAs for their effect on colony formation. As shown in
Figure 4a, after transfection of the specific siRNA
plasmids, all the four HPV-16-siRNAs (16E6-164, 16E6-
161, 16E7-629 and 16E7-628) caused significant inhibition
(480%) of colony formation compared with the control
vector (Figure 4a). Similarly, all the three HPV-18-
siRNAs (18E6-119, 18E7-666 and 18E7-674) caused
significant inhibition (490%) of colony formation
(Figure 4b). These siRNAs were also transfected into
the non-HPV-infected cells to test their specificity. As
shown, there was no significant effect (o 5%) on colony
formation in C33A cells by any of the seven HPV-siRNAs
(Figure 4c).
Vector
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6 12 18 24 6 12 18 24 6 12 18 24
16E6-249 16E6-164
Time (h)
16E6
Ratio
Actin
Vector 16E7-666 16E7-628
Time (h)
16E7
Ratio
Actin
Vector 18E7-665 18E7-666
Time (h)
18E7
Ratio
Actin
Vector 18E6-Scramble 18E6-119
Time (h)
18E6
Ratio
Actin
16E6-161
1.0 1.0 1.0 1.0
1.0 1.0 1.0 1.0
1.0 1.0 1.0 1.0
1.0 1.0 1.0 1.0
0.78 0.72 0.66 0.89 0.74 0.45 0.33 0.31 0.32 0.35 0.57 0.70
16E7-629
1.45 0.94 0.63 0.70 0.82 0.48 0.32 0.31 0.22 0.91 0.57 0.46
0.82 0.89 1.08 1.18 0.37 0.87 0.46 0.53
18E7-674
1.15 0.77 0.91 0.75 0.95 0.74 0.35 0.37 0.85 0.57 0.48 0.09
Figure 1 Knockdown of HPV-E6 or HPV-E7 gene expression by transfection of specific HPV-siRNAs. The silencing ability of each siRNA was
determined by RT-PCR analysis after transfection of 6mg of each siRNA plasmid for 6–24h. The identity of each siRNA is indicated at the top of
the bands. Actin gene expression was used as a control for each gene. The relative density of each sample is indicated at the bottom of each
band, normalized to the actin level in each individual sample. (a) Differential inhibition of HPV-16 E6 gene expression in Caski cells.
(b) Differential inhibition of HPV-16 E7 gene expression in Caski cells. (c) Differential inhibition of HPV-18 E6 gene expression in HeLa cells.
(d) Differential inhibition of HPV-18 E7 gene expression in HeLa cells.
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Because the targets of viral oncogenes E6 and E7 are p53
and pRb, which participate in cell cycle and apoptotic
regulatory pathways, we examined whether any of these
HPV-siRNAs have an effect on cell-cycle or apoptosis.
Cells were subjected to flow cytometry after transfection
by the specific HPV-siRNAs. As shown in Figure 5a, the
cells transfected with the control vector (Caski-U6II) have
a distinct peak at the G1 phase and a smaller peak at the
G2/M phase. In cells transfected with any of the HPV-16-
siRNAs (16E6-164, 16E6-161, 16E7-629 and 16E7-628),
both the G1 and G2/M peaks were diminished, whereas
the apoptotic fraction (M1 phase) was significantly
increased. At day 3, over 40% of cells transfected with
any of the four HPV-16-siRNAs were apoptotic. Simi-
larly, a substantial increase in the number of apoptotic
cells was induced by any of the three HPV-18-siRNAs
(18E6-119, 18E7-666 and 18E7-674) (Figure 5b). At day
3, over 70% of cells transfected with these siRNAs were
apoptotic. By contrast, there was almost no apoptosis
(o2%) in cells transfected with the scrambled plasmid
(Figure 5b). As for the specificity of these siRNAs, none
of the seven HPV-siRNAs had a significant effect on
apoptosis in non-HPV-infected cells (o2% of difference
compared with the non-transfected control) (Figure 5c).
Suppression of tumor growth in vivo by HPV-siRNAs
To investigate the effect of HPV-siRNAs on tumor
growth in vivo, two of the potent siRNAs against the
HPV-E6 and -E7 genes (18E6-119, 18E7-674) were used in
a xenograft model in BALB/C nude mice. Cancer cells
were subcutaneously injected in the upper portion of
both rear limbs. After 3 days, an HPV-siRNA was
administered to one tumor site and a control vector
plasmid was administered to the other to compare the
effect on tumor formation. Tumor sizes were continu-
ously monitored every 2–3 days for a total of 30 days.
Results are shown in the Figure 6. Although tumor size
varied between mice, we consistently found that tumor
growth was inhibited in the HPV-siRNA-treated cells.
With the HPV-18E6-119 siRNA, tumor growth was dec-
reased to 49% of the average at day 17 (Po0.001) and to
56% of the average at day 30 (Po0.001) (Figure 6a).
Similarly, tumor growth was inhibited by the HPV-18E7-
666 siRNA, to 48% of the average at day 17 (P¼0.0018)
and 54% of the average at day 30 (Po0.001) (Figure 6b).
These results demonstrate the effective suppression of
tumor growth in vivo by these HPV-siRNAs.
Discussion
Cervical cancer is the second most common cancer in
women worldwide and the majority of cases are caused
by high-risk types of human papillomavirus (HPV-16
and -18), which possess the E6 and E7 oncogenes. The
concurrent expression of E6 and E7 protein is a
prerequisite for cancer development and required to
maintain malignant phenotypes. Although the pap smear
screening test has recently become popular as a method to
reduce the incidence rate of cervical cancer, effective
therapy for cervical cancer is still urgently needed in
developing countries.
Figure 2 Comparable transfection efficacy among cells of HeLa, CaSki and C33A. A total of 1 10
6 cells (Caski or HeLa or C33A) were seeded
into a 100-mm
2 dish and incubate for 16h. The cells were then transfected with 6mg of pGFP plasmid for 12h. The medium was then replaced
with fresh medium and normal cell culture was resumed. After 24h, the cells were examined by a fluorescent microscopy (Nikon, Eclipse, TE300,
Nikon Precision Taiwan, Taipei, Taiwan) with visible light (upper panel) or fluorescent light (lower panel).
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plasmids against the E6 or E7 viral oncogenes in
HPV-16 and HPV-18 and found that all of them
effectively inhibit the expression of E6 or E7 in the
HPV-infected cervical cancer cells (Figure 1). Transfec-
tion of these siRNAs caused significant suppression of
both cell growth (Figures 3a-d) and colony formation
(Figures 4a and b) in HPV-positive cells, whereas they
had no effect in HPV-negative cells (Figures 3e, f and 4c),
demonstrating the effectiveness and specificity of these
siRNAs. In examining cell-cycle status, we found that
these HPV-siRNAs promoted the induction of apoptosis
in the HPV-infected cells (Figure 5). These results are
consistent with recent findings that the reduction of E6 or
E7 expression can induce apoptosis in HPV-positive
cells.
14–15 The mechanism by which E6 or E7 knockdown
induces apoptosis is unclear. Presumably, silencing of
E6 or E7 leads to an accumulation of p53 or pRB,
respectively, either of which may induce senescence or
apoptosis.
14,15,19 It is of note that the effect of these
siRNAs was specific to HPV-infected cells, as the non-
infected C33A cells remained unaltered in response to
siRNA transfection. These results demonstrate the
efficacy of our siRNA sequence design.
The design of an effective siRNA sequence is an
important issue. It is unfortunate that, no highly effective,
simple protocol exists thus far. The first requirement for
an effective siRNA sequence is that the siRNA must
target part of the open reading frame of the gene,
however, not all sites are effective. For example, in the
HPV16-E6 gene, the siRNAs 16E-164 or -161 are more
effective at silencing than 16E6-249. These results indicate
that the targeting sequences located 161–183 nucleotides
from the transcriptional start codon have stronger effects
than sequences located 249–267 nucleotides away
(Table 1). In the HPV16-E7 gene, the siRNAs 16E7-629
and  628 are more effective at silencing than 16E7-666.
Apparently, siRNAs targeted to sites 628–649 nucleotides
from the transcriptional start codon are more effective
than siRNAs targeted to sites 666–682 away (Table 1).
Similarly, siRNAs targeted to nucleotides 119–125 and
666–690 are effective for HPV18 E6 and E7 genes,
respectively (Table 1). The second requirement for an
effective siRNA sequence is that the length must be
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Figure 3 Cell growth was inhibited in HPV-positive cervical cancer cells by HPV-siRNAs. A total of 1 10
6 cells (Caski or HeLa or C33A) were
seeded into a 100-mm
2 dish. After transfection of a specific HPV-siRNA, cell numbers were counted every day for up to 3 days. (a) Differential
inhibition of cell growth by HPV-16E6-siRNAs in Caski cells. (b) Differential inhibition of cell growth by HPV-16E7-siRNAs in Caski cells.
(c) Differential inhibition of cell growth by HPV-18E6-siRNAs in HeLa cells. (d) Differential inhibition of cell growth by HPV-18E7-siRNAs in HeLa
cells. (e) Minimal effect of cell growth by HPV-16-siRNAs in non-HPV-infected C33A cells. (f) Minimal effect of cell growth by HPV-18-siRNAs in
non-HPV-infected C33A cells.
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Cancer Gene Therapybetween 17–22 nucleotides, however, there appears to be
no preference for a specific length within that range. This
can be demonstrated by comparing the knockdown of
two siRNAs against the HPV16 E7 gene. The siRNA
16E7-629 (17 nucleotides, targeting to 629–645) has a
similar silencing effect as the siRNA 16E7-628 (22
nucleotides, targeting 628–649). As comparing the silen-
cing effect of E6 and E7 genes, as E7 and E6 are
transcribed bicistronically,
20 an siRNA targeting to E7
may silence E6 as well, leading to a greater phenotypic
effect. In the present study, however, we found compar-
able effects on growth inhibition, apoptotic induction and
tumor suppression by either E6 or E7 knockdown
(Figures 3–6). This may be due to effective siRNA design
and optimized dosage, resulting in maximal gene suppres-
sion. Although the aim of this study was to discover
candidate siRNAs, the ultimate aim will be the applica-
tion of the high potent siRNAs to HPV-infected cancer
patients. For this, other siRNA delivery strategy, such
as lentiviral vector, may be good to use.
100% 91% 18% 19% 19% 17%
7% 100% 101% 100% 103% 8% 9%
99% 99% 100% 102% 101% 97% 100% 100%
Figure 4 Colony formation was inhibited in HPV-positive cervical cancer cells by HPV-siRNAs. A total of 1000 cells (Caski or HeLa or C33A)
transfected with a specific HPV-siRNA plasmid were seeded in six-well plates and allowed to grow for 10 days. The identity of each HPV-siRNA is
indicated at the top of each plate. Relative levels of colony formation were quantified and are shown below each plate. (a) Suppression of colony
formation by HPV-16-siRNAs in Caski cells. (b) Suppression of colony formation by HPV-18-siRNAs in Caski cells. (c) Minimal effect of colony
formation by HPV-siRNAs in non-HPV infected C33A cells.
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Figure 5 Induction of apoptosis in HPV-positive cervical cancer cells by HPV-siRNAs. A total of 1 10
6 cells (Caski or HeLa or C33A) were
transfected with a specific HPV-siRNA for 24h. The cells were then synchronized to G0 phase by replacing the culture medium with serum-free
medium for 12h. Cells were then continuously cultured in regular medium and subjected to flow cytometric analysis every 24h up to 72h. The M1
fraction in each graph indicates apoptotic cells, and the percentage of M1 cells is indicated in each figure. (a) Increase of apoptotic fractions by
HPV-16-siRNAs in Caski cells. (b) Increase of apoptotic fractions by HPV-18-siRNAs in HeLa cells. (c) Minimal effect of apoptosis by HPV-
siRNAs in C33A cells.
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Cancer Gene TherapyConsistent with our in vitro results, we found that
knockdown of HPV E6 or E7 expression by siRNA
delivery has potent anti-tumor effects, as measured
by significant suppression of xenograft tumor growth
(Figures 6a and b). As the E6 and E7 HPV oncogenes
share no sequence homology to human genes, silencing of
these oncogenes may be a highly effective molecular
therapy for cervical cancer without causing high toxicity
in normal cells. In conclusion, we have developed a series
of potent HPV-siRNAs that successfully suppress tumor
growth and induce apoptosis in HPV-positive cervical
cancer cells, while having minimal effect in HPV-negative
human cells. Given the immense interest in RNA inter-
ference as a potential therapeutic, these siRNAs may be
further developed as an adjuvant therapy for cervical cancer.
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Figure 6 Suppression of tumor growth in xenografts of HPV-
positive cervical cancer cells by HPV-siRNAs. BALB/c null mice
(seven in each group) were injected with 5 10
6 HeLa cells
subcutaneously to generate solid tumors at two sites. After 3 days,
30mg of either an HPV-18-siRNA or control vector plasmid in 30mlo f
normal saline solution was intra-tumorally injected, followed by
booster injections of 15mg of plasmid twice a week for 2 weeks. The
tumors were monitored for a total of 30 days. The tumor volume was
calculated as the length x width x height. Red lines: tumor growth
status in the mice injected with vector plasmid. Blue lines: tumor
growth status in the mice injected with HPV18-siRNA. (a) Effect of
18E6-119 siRNA on tumor growth. (b) Effect of 18E6-674 siRNA on
tumor growth.
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